Conference Correspondent

Beth Faiman reviews the steps she takes upon introducing patients to daratumumab. Read More ›

Perceptions of Daratumumab Therapy

By Beth Faiman, PhD, APRN-BC, AOCN

Hematologic Cancers, Conference Correspondent, ASH

Conference Correspondent

Beth Faiman sees daratumumab as a game changer for patients with multiple myeloma. Read More ›

Managing Patients with Multiple Myeloma

By Beth Faiman, PhD, APRN-BC, AOCN

Hematologic Cancers, Conference Correspondent, ASH

Conference Correspondent

Beth Faiman reflects on the considerations involved with managing patients who have experienced multiple myeloma relapses. Read More ›

BCOP Clinical Sessions: Lung Cancer Therapy and Molecular Targets

Conference Correspondent, ASHP

Conference Correspondent

Targeted therapy in the management of non–small-cell lung cancer is discussed. Read More ›

Real-World Impact of Prophylactic Pegfilgrastim in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Receiving Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With or Without Rituximab Chemotherapy in Korea

Conference Correspondent, ASHP

Conference Correspondent

Prophylactic pegfilgrastim was associated with fewer neutropenic events in patients receiving a CHOP-based regimen in DLBCL. Read More ›

Comparison of Efficacy and Cost-Effectiveness of Filgrastim, tbo-Filgrastim, and Filgrastim-sndz in Patients with Cancer Receiving Myelosuppressive Chemotherapy and Patients with Severe Chronic Neutropenia

Conference Correspondent, ASHP

Conference Correspondent

An analysis of the efficacy and cost-effectiveness of 3 colony-stimulating factors— filgrastim, tbo-filgrastim, and filgrastim-sndz—is presented. Read More ›

Personalizing Patient Management and Oral Adherence for the Oncology Patient

Conference Correspondent, ASHP

Conference Correspondent

The role of the oncology pharmacist in promoting oral adherence for the oncology patient is discussed. Read More ›

Latest Developments in Short-Acting Granulocyte Colony-Stimulating Factor (G-CSF) Treatment Options: The First FDA-Approved Biosimilar, Zarxio® (filgrastim-sndz)

Conference Correspondent, ASHP

Conference Correspondent

Biosimilarity between Zarxio and Neupogen is proven through PIONEER study results. Read More ›

Updated Analysis of the Efficacy of Daratumumab Combination Therapy in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy

Conference Correspondent, ASH

Conference Correspondent

Heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) derived significant benefit from a combination of daratumumab, dexamethasone, and bortezomib. These data continue to support the addition of daratumumab to a standard-of-care regimen in RRMM. Read More ›

Use of Montelukast to Reduce Infusion Reactions in Patients with Relapsed or Refractory Multiple Myeloma

Conference Correspondent, ASH

Conference Correspondent

Administration of the asthma medication montelukast more than 30 minutes before infusion of daratumumab can drastically reduce infusion-related reactions in patients with multiple myeloma.

Subscribe Today!

I'd like to receive:

Page 5 of 12

Subscribe Today!

I'd like to receive: